Free tool
FAERS Monitor: Trulicity
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 125469 or its brand name (Trulicity, Dulaglutide). Reports on generic versions are filed under their own applications.
Reports
89,369
Serious
23,531
26% of reports
Hospitalization
11,056
Death reported
1,706
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- nausea10,580
- injection site pain10,019
- blood glucose increased9,960
- diarrhoea6,200
- vomiting5,949
- incorrect dose administered5,663
- inappropriate schedule of product administration3,843
- drug ineffective3,757
- weight decreased3,438
- decreased appetite3,281
- extra dose administered3,202
- injection site haemorrhage3,179
- glycosylated haemoglobin increased2,979
- abdominal pain upper2,512
- fatigue2,489
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2011 | 1 |
| 2012 | 4 |
| 2014 | 14 |
| 2015 | 1,678 |
| 2016 | 3,893 |
| 2017 | 6,225 |
| 2018 | 7,421 |
| 2019 | 9,334 |
| 2020 | 10,676 |
| 2021 | 12,619 |
| 2022 | 11,157 |
| 2023 | 9,512 |
| 2024 | 7,287 |
| 2025 | 5,875 |
| 2026 | 3,673 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,964,790 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| glycosylated haemoglobin increasedSignal | 2,979 | 31.4 | 30.2 | 77,310 |
| extra dose administeredSignal | 3,202 | 20.1 | 19.4 | 53,651 |
| blood glucose increasedSignal | 9,960 | 13.1 | 12.8 | 106,183 |
| injection site haemorrhageSignal | 3,179 | 9.7 | 9.4 | 23,944 |
| injection site painSignal | 10,019 | 7.9 | 7.8 | 59,391 |
| incorrect dose administeredSignal | 5,663 | 6.0 | 5.8 | 23,051 |
| inappropriate schedule of product administrationSignal | 3,843 | 5.1 | 4.9 | 12,522 |
| decreased appetiteSignal | 3,281 | 3.4 | 3.2 | 5,413 |
| nauseaSignal | 10,580 | 3.2 | 3.1 | 16,161 |
| vomitingSignal | 5,949 | 3.0 | 2.9 | 8,026 |
| weight decreasedSignal | 3,438 | 2.9 | 2.8 | 4,349 |
| abdominal pain upperSignal | 2,512 | 2.9 | 2.8 | 3,105 |
| diarrhoeaSignal | 6,200 | 2.3 | 2.2 | 4,514 |
| fatigue | 2,489 | 0.8 | 0.7 | 211 |
| drug ineffective | 3,757 | 0.7 | 0.6 | 649 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.